➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Mallinckrodt
McKinsey
Harvard Business School
Dow

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for CC-486


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug CC-486?

CC-486 is an investigational drug.

There have been 27 clinical trials for CC-486. The most recent clinical trial was a Phase 1 trial, which was initiated on June 14th 2019.

The most common disease conditions in clinical trials are Lymphoma, Leukemia, and Preleukemia. The leading clinical trial sponsors are Celgene Corporation, Celgene, and National Cancer Institute (NCI).

There are twenty-two US patents protecting this investigational drug and one hundred and ninety-six international patents.

Recent Clinical Trials for CC-486
TitleSponsorPhase
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)AbbViePhase 1
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)CelgenePhase 1
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaNational Cancer Institute (NCI)Phase 2/Phase 3

See all CC-486 clinical trials

Clinical Trial Summary for CC-486

Top disease conditions for CC-486
Top clinical trial sponsors for CC-486

See all CC-486 clinical trials

US Patents for CC-486

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-486   Get Started Free Remote loading of sparingly water-soluble drugs into lipid vesicles ZONEONE PHARMA, INC. (San Francisco, CA)   Get Started Free
CC-486   Get Started Free Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA)   Get Started Free
CC-486   Get Started Free Tumor-selective combination therapy The Board of Regents of the University of Texas System (Austin, TX) The Board of Trustees of the University of Illinois. (Urbana, IL)   Get Started Free
CC-486   Get Started Free Remote loading of sparingly water-soluble drugs into liposomes ZONEONE PHARMA, INC. (San Francisco, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-486

Drugname Country Document Number Estimated Expiration Related US Patent
CC-486 Australia AU2015301234 2034-08-04   Get Started Free
CC-486 Canada CA2962709 2034-08-04   Get Started Free
CC-486 China CN106999419 2034-08-04   Get Started Free
CC-486 European Patent Office EP3177269 2034-08-04   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKesson
AstraZeneca
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.